- Home
- SLVM vs IMTX Comparison
SLVM vs IMTX Comparison
Compare SLVM & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLVM | IMTX |
|---|---|---|
| Founded | 1898 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SLVM | IMTX |
|---|---|---|
| Price | $41.61 | $9.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $54.00 | $19.00 |
| AVG Volume (30 Days) | 350.0K | ★ 527.9K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,351,000,000.00 | N/A |
| Revenue This Year | $0.93 | N/A |
| Revenue Next Year | $1.54 | $25.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.53 | $5.05 |
| 52 Week High | $56.80 | $12.41 |
Technical Indicators
Market Signals| Indicator | SLVM | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 37.00 |
| Support Level | $39.94 | $9.05 |
| Resistance Level | $44.05 | $10.64 |
| Average True Range (ATR) | 1.32 | 0.59 |
| MACD | 0.49 | -0.20 |
| Stochastic Oscillator | 92.64 | 19.11 |
Price Performance
Historical ComparisonAbout SLVM Sylvamo Corporation
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.